The increased risk for metachronous colorectal neoplasms after polypectomy in patients with metabolic dysfunction–associated steatotic liver disease can be ameliorated in a dose-dependent manner if metabolic dysfunction is improved, according to the results of a large study from Taiwan.
“Interventions for reducing metabolic dysfunction during the surveillance interval can be regarded as a strategy of primary prevention against metachronous [colorectal] neoplasms in MASLD